We anticipate that the initial public offering price of our common shares will be between $14.00 and $16.00 per share.We have been approved to list our common shares on the New York Stock Exchange under the symbol "BHVN."We are an "emerging growth company" as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public
We believe the strength of our management team and board of directors positions us well to enter into additional license and collaboration arrangements with world-class institutions.6Table of ContentsRisks Associated with Our BusinessOur business is subject to a number of risks of which you should be aware before making a decision to invest in our common shares.
candidates or technology from third parties or, in certain cases, we fail to meet certain development deadlines, we could lose license rights that are important to our business.•There has been no public market for our common shares prior to this offering, and an active market in the shares may not develop or be liquid
our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common shares.Corporate InformationWe were incorporated as a business company limited by shares organized under the laws of the British Virgin Islands in September 2013.
with correspondingly reduced "Management's Discussion and Analysis of Financial Condition and Results of Operations" disclosure in this prospectus;•not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended;•reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and•exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden
elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.9Table of ContentsTHE OFFERINGCommon shares offered8,333,333 sharesCommon shares outstanding after this offering32,663,916 shares (33,913,916 shares if the underwriters exercise their over-allotment option in full)Over-allotment optionWe have granted the underwriters the option, exercisable for 30 days from the date of this prospectus, to purchase up to 1,250,000 additional common shares.Use of proceedsWe expect the net proceeds from this offering to be approximately $112.6 million, based on an assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after
notes payable to related parties; to satisfy our obligation to purchase shares of capital stock of a privately held preclinical-stage company; and for working capital and other corporate purposes, including satisfaction of any of our milestone
agreements with BMS and AstraZeneca;•no exercise of the outstanding options and warrants described above; and•no exercise of the underwriters' over-allotment option.Certain of our existing principal shareholders, directors and their affiliated entities have indicated an interest in purchasing up to an aggregate of $70.0 million in common
Our historical results are not necessarily indicative of results that may be expected in any future period.Year EndedDecember 31,20152016(in thousands, exceptper share data)Consolidated Statement of Operations Data:Operating expenses:Research and development$7,559$55,529General and administrative2,1375,109​​​​​​​​Total operating expenses9,69660,638​​​​​​​​Loss from operations(9,696)(60,638)Other income (expense), net(370)(2,806)​​​​​​​​Loss before provision for income taxes(10,066)(63,444)Provision for income taxes—90​​​​​​​​Net loss(10,066)(63,534)Less: Net income (loss) attributable to non-controlling interests(4)143​​​​​​​​Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.$(10,062)$(63,677)​​​​​​​​​​​​​​​​​​​​​​​​Net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.—basic and diluted(1)$(0.91)$(5.05)​​​​​​​​​​​​​​​​​​​​​​​​Weighted average common shares outstanding—basic and diluted(1)11,00912,608​​​​​​​​​​​​​​​​​​​​​​​​Pro forma net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.—basic and diluted
common shareholders of Biohaven Pharmaceutical Holding Company Ltd.12Table of ContentsAs of December 31, 2016ActualPro Forma(2)Pro FormaAs Adjusted(3)(in thousands)Consolidated Balance Sheet Data:Cash$23,565$62,200$169,225Working capital(1)16,09354,728166,103Total assets27,01765,652172,543Notes payable, net of discount4,2164,216—Notes payable to related parties595595—Warrant liability780780780Contingent equity liability18,938——Convertible preferred shares43,270——Total shareholders' equity (deficit)(45,033)55,810167,646(1)We
business, financial condition or results of operations could suffer, the price of our common shares could decline and you could lose part or all of your investment.Risks Related to Our Financial Position and Need for Additional CapitalWe have a limited operating history and have never generated any product revenues, which may make it
in-licensing the rights to, and advancing the development of, our product candidates, including conducting preclinical studies and clinical trials.
successfully complete later-stage clinical trials, obtain marketing approvals, manufacture products on a commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and
will increase substantially as we:•continue the development of our product candidates, including the initiation of two Phase 3 clinical trials and a long-term safety study
candidates that we may pursue;14Table of Contents•continue to build our portfolio of product candidates through the acquisition or in-license of additional product candidates or technologies;•continue to develop, maintain, expand and protect our intellectual property portfolio;•pursue regulatory approvals for our current and future product candidates that successfully complete clinical trials;•ultimately establish a sales, marketing and distribution infrastructure to commercialize any product candidate for which we may obtain
range of challenging activities, including completing clinical trials of our product candidates, developing commercial scale manufacturing processes, obtaining marketing approval, manufacturing,
If we are unable to raise capital when needed or on terms favorable to us, we could be forced to curtail our planned operations and the pursuit of our growth strategy.Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain
Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company.As of December 31, 2016, we had cash of $23.6 million, and in February 2017, we received net cash proceeds of $38.6 million from the sale of Series A
Our future capital requirements will depend on many factors, including:•the scope, progress, results and costs of our ongoing and planned preclinical studies and clinical trials for our product candidates;•the timing and amount of milestone and royalty payments we are required to make under our license agreements;•the extent to which we in-license or acquire other product candidates and technologies;•the number and development requirements of other product candidates that we may pursue, and other indications for our current product
product candidates for which we receive marketing approval;•the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;•our ability to establish strategic collaborations for the development or commercialization of some of our product candidates; and•the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and
if this offering is successful, we will require additional capital to complete our planned clinical development programs for our current product candidates to seek regulatory
programs or the commercialization of any product candidates, if approved, or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired.Our independent registered public accounting firm has included an explanatory paragraph relating to our
our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all.We are subject to significant obligations, including to potentially make significant payments under the
addition, our license agreements with BMS and AstraZeneca obligate us to use commercially reasonable efforts to develop and commercialize product candidates, to provide BMS and
valuable rights to our intellectual property future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us.Risks Related to the Development of Our Product CandidatesWe depend entirely on the success of a limited number of product candidates, which are in clinical
The success of our product candidates will depend on several additional factors, including:•completing clinical trials that demonstrate their efficacy and safety;•receiving marketing approvals from applicable regulatory authorities;•completing any post-marketing studies required by applicable regulatory authorities;•establishing commercial manufacturing capabilities;•launching commercial sales, marketing and distribution operations;•the prevalence and severity of adverse events experienced with our product candidates;•acceptance of our product candidates by patients, the medical community and third-party payors;•a continued acceptable safety profile following approval;•obtaining and maintaining healthcare coverage and adequate reimbursement for our product candidates;•competing effectively with other therapies, including with respect to the sales and marketing of our product candidates, if approved; and•qualifying for, maintaining, enforcing and defending our intellectual property rights and claims.Many
obtain regulatory approval or, if approved, commercialize our product candidates, which would materially harm our business, financial condition and results of operations.Clinical trials are very expensive, time-consuming and difficult to design and implement and involve
timeline and regulatory approval and commercialization prospects for our product candidates, and, correspondingly, our business and financial prospects, would be materially adversely affected.We have limited experience in drug discovery and drug development, and we have never had a drug approved.Because we in-licensed rimegepant and BHV-3500 from BMS and BHV-5000 from AstraZeneca, we were not involved in and had no control over the
and costs may be increased, which could adversely affect our prospects for marketing approval of, and receiving any future revenue from, these product candidates.Clinical trials may be delayed, suspended or terminated for many reasons, which will increase our expenses
completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenue from
foreign regulatory agency can delay, limit or deny approval of our product candidates or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons,
cause undesirable side effects, a number of potentially significant negative consequences could result, including:•withdrawal or limitation by regulatory authorities of approvals of such product;•seizure of the product by regulatory authorities;•recall of the product;•restrictions on the marketing of the product or the manufacturing process for any component thereof;•requirement by regulatory authorities of additional warnings on the label, such as a "black box" warning or contraindication;•requirement that we implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients;•commitment to expensive additional safety studies prior to approval or post-marketing studies required by regulatory authorities of such
candidates, either before or after receipt of marketing approval, could have a material adverse effect on the development of our drug candidates and our business as a whole.We depend on enrollment of patients in our clinical trials for our product candidates.
therapies, including any new drugs that may be approved for the indications we are investigating or drugs that may be used off-label for these indications;•the size of the patient population required for analysis of the trial's primary endpoints;•competition for patients for competitive product candidates undergoing clinical trials;•the efforts to facilitate timely enrollment in clinical trials;•the design of the trial;•the patient referral practices of physicians;•our ability to recruit clinical trial investigators with the appropriate competencies and experience;•the ability to monitor patients adequately during and after treatment;•the risk that patients enrolled in clinical trials will drop out of the trials before completion;•the ability to obtain and maintain patient consents;•the number of patients with the indication being studied; and27Table of Contents•the proximity and availability of clinical trial sites for prospective patients.In
highly dependent upon our ability to in-license, acquire, develop and obtain regulatory approval for new and innovative products on a cost-effective basis and to market them successfully.
existing or subsequently introduced drugs would harm our business, financial condition and results of operations.30Table of ContentsThe successful commercialization of certain of our product candidates will depend in part on the extent to
acceptance of our product candidates that are approved for commercial sale will depend on a variety of factors, including:•the efficacy and potential advantages compared to alternative treatments;•effectiveness of sales and marketing efforts;•the cost of treatment in relation to alternative treatments, including any similar generic treatments;•our ability to offer our products, if approved, for sale at competitive prices;•the convenience and ease of administration compared to alternative treatments;•the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;•the strength of marketing and distribution support;•the availability of third-party coverage and adequate reimbursement, and patients' willingness to pay out-of-pocket in the absence of
including:•an inability to initiate or continue clinical trials of our product candidates under development;•delay in submitting regulatory applications, or receiving regulatory approvals, for our product candidates;•subjecting third-party manufacturing facilities or our own facilities to additional inspections by regulatory authorities;•requirements to cease distribution or to recall batches of our product candidates;•suspension of manufacturing of our product candidates;•revocation of obtained approvals; and•inability to meet commercial demands for our product candidates in the event of approval.Furthermore,
solution in time, our clinical trials could be delayed or our commercial activities could be harmed.37Table of ContentsIn addition, the fact that we are dependent on third parties for the manufacture, storage and distribution of our product candidates means that we are subject to
candidates receive regulatory approval; and we expect to rely on third parties for supply, manufacturing and distribution of preclinical, clinical and commercial supplies of any future product
Collaborations are subject to numerous risks, including:•collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;•collaborators may not perform their obligations as expected;•the clinical trials conducted as part of these collaborations may not be successful;40Table of Contents•collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to
individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer's Medicaid rebate liability;•expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;•a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research,
concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.Risks Related to Our Intellectual PropertyIf we are unable to obtain and maintain patent protection for our technology and product candidates, or if
in-license may fail to result in issued patents with claims that cover our current and future product candidates in the United States or in other foreign countries.
agreements, termination may also result in the transfer of or granting in rights under certain of our intellectual property and information related to the product candidate being developed under the
important intellectual property or technology or impede, delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements.Intellectual property rights do not necessarily address all potential threats to our business.Once granted, patents may remain open to invalidity challenges including opposition, interference, re-examination, post-grant review, inter
countries;61Table of Contents•different medical practices and customs in foreign countries affecting acceptance in the marketplace;•tariffs and trade barriers;•other trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or foreign governments;•longer accounts receivable collection times;•longer lead times for shipping;•compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;•workforce uncertainty in countries where labor unrest is common;•language barriers for technical training;•reduced protection of intellectual property rights in some foreign countries, and related prevalence of generic alternatives to therapeutics;•foreign currency exchange rate fluctuations and currency controls;•differing foreign reimbursement landscapes;•uncertain and potentially inadequate reimbursement of our products; and•the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.Foreign
The market price of our common shares may fluctuate significantly due to a variety of factors, including:•positive or negative results of preclinical studies and clinical trials reported by us, strategic partners or competitors;•any delay in the commencement, enrollment and the ultimate completion of clinical trials;•technological innovations or commercial product introductions by us or competitors;•failure to successfully develop and commercialize any of our product candidates;•developments, announcements or changes in government regulations relating to drug products, including related to drug pricing, reimbursement
and healthcare coverage;•delays in in-licensing or acquiring additional complementary product candidates;•developments concerning proprietary rights, including patents and litigation matters;•public concern relating to the commercial value or safety of any of our product candidates;•financing or other corporate transactions, or inability to obtain additional funding;•failure to meet or exceed expectations of the investment community;•announcements by therapeutic drug product providers related to pricing of therapeutics;•announcements of significant licenses, acquisitions, strategic partnerships or joint ventures by us or our competitors;•publication of research reports or comments by securities or industry analysts;•general market or regulatory conditions in the pharmaceutical industry or in the economy as a whole; or64Table of Contents•other events and factors, many of which are beyond our control.These
may be beneficial to our shareholders, more difficult and may prevent attempts by our shareholders to replace or remove our current management and limit the market price of our common shares.Provisions in our memorandum and articles of association that will become effective upon the closing of this offering may discourage, delay or
timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting, and our share price may decline as a result.You may have fewer protections as a shareholder of our company, as the rights of shareholders under British
These forward-looking statements include, but are not limited to, statements concerning the following:•our plans to develop and commercialize our product candidates;•our planned clinical trials for our rimegepant, trigriluzole, BHV-0223 and BHV-5000 development programs;•the timing of the availability of data from our clinical trials;•the timing of our planned regulatory filings;•the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;•the clinical utility of our product candidates;•our commercialization, marketing and manufacturing capabilities and strategy;•our intellectual property position;•our estimates regarding future revenues, expenses and needs for additional financing; and•the potential purchases of common shares by certain of our existing principal shareholders, directors and their affiliated entities in this
currently estimate that we will use the net proceeds from this offering, together with our existing cash, as follows:•approximately $73.1 million to fund continued research and development of rimegepant, including initiating and completing our two
of this prospectus titled "Selected Consolidated Financial Data," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Description of Share Capital."As of December 31, 2016ActualPro FormaPro FormaAs Adjusted(1)(in thousands, except share and pershare data)Cash$23,565$62,200$169,225​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Notes payable, net of discount$4,216$4,216$—Notes payable to related parties595595—Warrant liability780780780Contingent equity liability18,938——Series A convertible preferred shares, no par value; 11,242,172 shares authorized, 4,948,369 shares issued and outstanding, actual; no shares authorized,
If our development efforts for our product candidates are successful and result in regulatory approval or additional license agreements with third parties, we may generate revenue in the
and development functions;•costs related to compliance with regulatory requirements;•facilities costs, depreciation and other expenses, which include rent and utilities; and•payments made in cash, equity securities or other forms of consideration under third-party licensing agreements.We
substantially over the next several years as we increase personnel costs, including share-based compensation, commence Phase 3 clinical trials of rimegepant, continue our ongoing
activities;•establishing an appropriate safety profile with IND-enabling studies;•successful patient enrollment in, and the initiation and completion of, clinical trials;•the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;•establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;•development and timely delivery of commercial-grade drug formulations that can be used in our clinical trials and for commercial launch;•obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;•significant and changing government regulation;•launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and•maintaining a continued acceptable safety profile of the product candidates following approval.We
planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.
BPI, at the applicable interest rate.Change in Fair Value of Warrant LiabilityIn connection with entering into our credit agreement with Wells Fargo, we agreed to issue warrants to purchase our common shares to the
the derivative liability until a change-of-control event occurs.Change in Fair Value of Contingent Equity LiabilityOur license agreements with BMS and AstraZeneca require us to issue shares of capital stock upon the occurrence of specified financing or
We will continue to recognize changes in the fair values of the contingent equity liabilities until the occurrence of a respective triggering event.Loss from Equity Method InvestmentIn August 2016, we executed a stock purchase agreement with Kleo Pharmaceuticals, Inc., or Kleo, to purchase shares of common stock in an
longer report any non-controlling interests related to BPI.Results of OperationsComparison of the Years Ended December 31, 2015 and 2016The following table summarizes our results of operations for the years ended December 31, 2015 and 2016:Year EndedDecember 31,20152016Change(in thousands)Operating expenses:Research and development$7,559$55,529$47,970General and administrative2,1375,1092,972​​​​​​​​​​​Total operating expenses9,69660,63850,942​​​​​​​​​​​Loss from operations(9,696)(60,638)(50,942)​​​​​​​​​​​Other income (expense):Interest expense—(385)(385)Change in fair value of warrant liability—154154Change in fair value of derivative liability(370)(65)305Change in fair value of contingent equity liability—(2,263)(2,263)Loss from equity method investment—(247)(247)​​​​​​​​​​​Total other income (expense), net(370)(2,806)(2,436)​​​​​​​​​​​Loss before provision for income taxes(10,066)(63,444)(53,378)Provision for income taxes—9090​​​​​​​​​​​Net loss(10,066)(63,534)(53,468)Less: Net income (loss) attributable to non-controlling interests(4)143147​​​​​​​​​​​Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.$(10,062)$(63,677)$(53,615)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Research and Development ExpensesYear EndedDecember 31,20152016Change(in thousands)Direct research and development expenses by program:BHV-0223$1,627$380$(1,247)Rimegepant—25,13925,139Trigriluzole3,49711,7618,264BHV-5000—13,55013,550Research and discovery and unallocated costs:Personnel related (including share-based compensation)1,9154,1372,222Other52056242​​​​​​​​​​​Total research and development expenses$7,559$55,529$47,970​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​94Table of ContentsResearch
common shares and net proceeds of $0.5 million from the collection of a note receivable from Portage Biotech, Inc. in connection with its initial equity investment in our company.Credit AgreementOn August 30, 2016, we entered into a one-year credit agreement with Wells Fargo providing for a term loan in the principal amount of
marketing approval and intend to commercialize on our own or jointly;•hire additional clinical, medical, and development personnel;•expand our infrastructure and facilities to accommodate our growing employee base;•transition our organization to being a public company;•maintain, expand and protect our intellectual property portfolio; and•acquire or in-license other product candidates and technologies.We believe that the anticipated net proceeds from this offering, together with our existing cash, will enable us to repay our indebtedness and to fund our operating expenses and capital
$0.8 million, and to pay royalties based on net sales of products at a low single-digit percentage, subject to a minimum amount of up to $0.1 million per year.Critical Accounting Policies and Significant Judgments and EstimatesOur consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States.
candidates;•our stage of development and commercialization and our business strategy;•external market conditions affecting the biotechnology industry, and trends within the biotechnology industry;•our financial position, including cash on hand, and our historical and forecasted performance and operating results;•the lack of an active public market for our common shares and our preferred shares;•the likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or a sale of our company in light of prevailing
Changes to these assumptions could have a significant impact on the fair value of the derivative liability.Valuation of Contingent Equity LiabilityOur license agreements with BMS and AstraZeneca require us to issue shares of capital stock upon the occurrence of specified financing or
on the results from the Phase 2b trial and earlier-stage development, we believe rimegepant offers the following clinical and product benefits for the acute treatment of
on the results from the Phase 2b trial and earlier-stage development, we believe rimegepant offers the following clinical and product benefits for the acute treatment of
BMS selected rimegepant as a lead CGRP receptor antagonist compound for its potential best-in-class chemical profile after 10 years of research on this drug target.Phase 2b Clinical Trial Design and ResultsRimegepant is being developed for oral administration and was observed to have evidence of comprehensive and durable treatment effect in a large
In satisfaction of this obligation, we expect that we will issue 1,345,374 common shares to BMS in connection with the closing of this offering.Right of First NegotiationAfter we receive topline data from a Phase 3 trial of our most advanced product candidate licensed under the agreement, we must provide
additional time period, we will have the sole right, in our discretion, to negotiate and execute any agreement with third parties, or to retain our rights.Equity ConsiderationAs part of the consideration, we agreed to issue to AstraZeneca common shares in the amount of $5.0 million if we completed a financing
of a Phase 3 trial related to products licensed under the agreement, and such change of control or sale results in a full liquidation of our company, we will be obligated to pay Rutgers a
The FDA may also require companies to perform additional studies or measurements, including clinical trials, to support the change from the approved branded reference drug.
purchased by any director or officer, which will be subject to the lock-up restrictions described in the "Underwriting" section of this prospectus.Relationship with Yale UniversityIn 2013, we entered into a license agreement with, and issued common shares to, Yale University, pursuant to which Yale became a holder of more
offering, or the perception that these sales could occur, could adversely affect prevailing market prices for our common shares and could impair our future ability to raise equity capital.Based on the number of shares outstanding as of February 28, 2017, upon completion of this offering and assuming no exercise of the underwriters' option to purchase additional
regarding the applicability of the Medicare tax to its income and gains in respect of its investment in our common shares.Passive Foreign Investment Company ConsiderationsWe do not believe we were a PFIC for our taxable year ended December 31, 2016 and based on the current and anticipated value of our
Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to
Changes in the fair value of the derivative liability will continue to be recognized until a change-of-control event occurs.Contingent Equity LiabilityThe Company's license agreements with AstraZeneca and BMS (see Note 13) require the Company to issue shares of capital stock upon the